Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Jan 08, 2024

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference

– Unaudited 2023 total revenue of $ 946 million, representing 35% year-over-year growth – – Regulatory filings in the EU and US for sepiapterin in PKU, a potential $1 billion global commercial opportunity, remain on track for 2024 – – Multiple study readouts planned for 2024, including

Jan 03, 2024

PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference

SOUTH PLAINFIELD, N.J. , Jan. 3, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 8 , at 7:30 a.m. PST / 10:30 a.m. EST .

Dec 14, 2023

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , Dec. 14, 2023 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on Dec. 10, 2023 , the company approved non-statutory stock options to purchase an aggregate of 3,575 shares of its common stock and 3,035 restricted stock units ("RSUs"), each

Dec 05, 2023

PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities

SOUTH PLAINFIELD, N.J. , Dec. 5, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States . As planned, PTC has submitted the briefing document as part of the re-examination of the initial

Nov 03, 2023

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , Nov. 3, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 1, 2023 , the company approved non-statutory stock options to purchase an aggregate of 14,005 shares of its common stock and 19,125 restricted stock units ("RSUs"), each

Oct 26, 2023

PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results

– Third quarter 2023 total revenues of $197 million and remain on target for 2023 revenue guidance – – PTC strengthened its financial position following recent restructuring initiatives and Royalty Pharma transaction – – PTC provides regulatory updates for pipeline programs – SOUTH PLAINFIELD, N.J.

Oct 19, 2023

PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion

- PTC to receive $1B in upfront cash for approximately 67% of outstanding royalties, with option for additional $500M - - Financing proceeds will be used to retire Blackstone debt obligations and fund planned operations - SOUTH PLAINFIELD, N.J. , Oct.

Oct 16, 2023

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results

SOUTH PLAINFIELD, N.J. , Oct. 16, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Oct.

Sep 28, 2023

PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce

- Translarna CHMP opinion re-examination request to be submitted - SOUTH PLAINFIELD, N.J. , Sept. 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today further strategic prioritization and associated workforce reduction. The portfolio prioritization continues the process

Sep 15, 2023

CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization

- Conference call to be held at 8: 45 am EDT - SOUTH PLAINFIELD, N.J. , Sept. 15, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on the

Pagination

First page
Previous page
…
Page 3
Page 4
Current page 5
Page 6
Page 7
…
Next page
Last page